Dyslipidemia Articles

Articles
The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias
Tokgözoğlu L, Orringer C, Catapano AL
Journal:
Eur Heart J

First published: December 28, 2023 DOI: 10.1093/eurheartj/ehad837
View
- Share
Articles
Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia
Corpeleijn WE, de Waal WJ, Schipper HS, et al.
Journal:
Diabetologia

First published: November 30, 2023 DOI: 10.1007/s00125-023-06041-z
View
- Share
Articles
Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis
Pamporis K, Karakasis P, Simantiris S, et al.
Journal:
Clin Investig Arterioscler

First published: November 30, 2023 DOI: 10.1016/j.arteri.2023.11.003
View
- Share
Articles
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
Moon JS, Park IR, Kim SS, et al.
Journal:
Diabetes Metab J

First published: November 24, 2023 DOI: 10.4093/dmj.2023.0171
View
- Share
Articles
2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP)
Journal:
Arch Med Sci

First published: November 2, 2023 DOI: 10.5114/aoms/174743
View
- Share
Articles
The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Chan DC, Watts GF
Journal:
Clin Ther

First published: July 29, 2023 DOI: 10.1016/j.clinthera.2023.07.008
View
- Share
Articles
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
Nissen SE, Menon V, Nicholls SJ, et al.
Journal:
JAMA

First published: June 24, 2023 DOI: 10.1001/jama.2023.9696
View
- Share
Articles
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
Kirkpatrick CF, Sikand G, Petersen KS, et al.
Journal:
J Clin Lipidol

First published: June 2, 2023 DOI: 10.1016/j.jacl.2023.05.099
View
- Share
Articles
Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers
Tokgozoglu L, Morrow DA, Nicholls SJ
Journal:
Eur Heart J

First published: June 1, 2023 DOI: 10.1093/eurheartj/ehad275
View
- Share
Articles
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.
Journal:
J Clin Lipidol

First published: May 31, 2023 DOI: 10.1016/j.jacl.2023.05.098
View
- Share
Articles
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease
Krishnaraj A, Bakbak E, Teoh H, et al.
Journal:
Med (N Y)

First published: January 10, 2023 DOI: 10.1016/j.medj.2022.12.008
View
- Share
Articles
The year in cardiovascular medicine 2022: the top 10 papers in dyslipidaemias
Tokgozoglu L, Orringer C, Catapano A
Journal:
Eur Heart J

First published: January 2, 2023 DOI: 10.1093/eurheartj/ehac750
View
- Share

1 2 3 4

Dyslipidemia Articles

Articles

The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias

Tokgözoğlu L, Orringer C, Catapano AL

Articles

Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia

Corpeleijn WE, de Waal WJ, Schipper HS, et al.

Articles

Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis

Pamporis K, Karakasis P, Simantiris S, et al.

Articles

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study

Moon JS, Park IR, Kim SS, et al.

Articles

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP)

Articles

The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies

Chan DC, Watts GF

Articles

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

Nissen SE, Menon V, Nicholls SJ, et al.

Articles

Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association

Kirkpatrick CF, Sikand G, Petersen KS, et al.

Articles

Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers

Tokgozoglu L, Morrow DA, Nicholls SJ

Articles

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.

Articles

Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease

Krishnaraj A, Bakbak E, Teoh H, et al.

Articles

The year in cardiovascular medicine 2022: the top 10 papers in dyslipidaemias

Tokgozoglu L, Orringer C, Catapano A

Articles

The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias

Tokgözoğlu L, Orringer C, Catapano AL

Share

Articles

Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia

Corpeleijn WE, de Waal WJ, Schipper HS, et al.

Share

Articles

Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis

Pamporis K, Karakasis P, Simantiris S, et al.

Share

Articles

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study

Moon JS, Park IR, Kim SS, et al.

Share

Articles

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Banach M, Surma S, Toth PP; endorsed by the International Lipid Expert Panel (ILEP)

Share

Articles

The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies

Chan DC, Watts GF

Share

Articles

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

Nissen SE, Menon V, Nicholls SJ, et al.

Share

Articles

Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association

Kirkpatrick CF, Sikand G, Petersen KS, et al.

Share

Articles

Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers

Tokgozoglu L, Morrow DA, Nicholls SJ

Share

Articles

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.

Share

Articles

Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease

Krishnaraj A, Bakbak E, Teoh H, et al.

Share

Articles

The year in cardiovascular medicine 2022: the top 10 papers in dyslipidaemias

Tokgozoglu L, Orringer C, Catapano A

Share